Preliminary radiogenomic study of hepatitis B virus-related hepatocellular carcinoma: associations between MRI features and mutations.

IF 1.7 4区医学 Q3 PHARMACOLOGY & PHARMACY

Personalized medicine Pub Date : 2023-05-01 DOI:10.2217/pme-2022-0093

Shanshan Gao, Feihang Wang, Wei Sun, Xianling Qian, Yuan Ji, Yunfeng Cheng, Xiaolin Wang, Lingxiao Liu, Ruofan Sheng, Mengsu Zeng

{"title":"Preliminary radiogenomic study of hepatitis B virus-related hepatocellular carcinoma: associations between MRI features and mutations.","authors":"Shanshan Gao, Feihang Wang, Wei Sun, Xianling Qian, Yuan Ji, Yunfeng Cheng, Xiaolin Wang, Lingxiao Liu, Ruofan Sheng, Mengsu Zeng","doi":"10.2217/pme-2022-0093","DOIUrl":null,"url":null,"abstract":"Aim: To investigate associations between MRI features and high-frequency mutations of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Methods: This study included 58 HCC patients who underwent contrast-enhanced MRI prior to surgical resection and genome sequencing. MRI features and mutation information were evaluated. Results: The top five most frequently mutated genes in HCC were TP53 (53.45%), TAF1 (24.14%), PDE4DIP (22.41%), ABCA13 (18.97%) and LRP1B (17.24%). Mutations in TP53 and LRP1B were associated with tumor necrosis (p = 0.035) and mosaic architecture (p = 0.015), respectively. Mutations in ABCA13 were associated with mosaic architecture (p = 0.025) and necrosis (p = 0.010). Conclusion: This preliminary radiogenomics analysis showed associations between MRI features and high-frequency mutations in HBV-related HCCs.","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Personalized medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pme-2022-0093","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To investigate associations between MRI features and high-frequency mutations of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Methods: This study included 58 HCC patients who underwent contrast-enhanced MRI prior to surgical resection and genome sequencing. MRI features and mutation information were evaluated. Results: The top five most frequently mutated genes in HCC were TP53 (53.45%), TAF1 (24.14%), PDE4DIP (22.41%), ABCA13 (18.97%) and LRP1B (17.24%). Mutations in TP53 and LRP1B were associated with tumor necrosis (p = 0.035) and mosaic architecture (p = 0.015), respectively. Mutations in ABCA13 were associated with mosaic architecture (p = 0.025) and necrosis (p = 0.010). Conclusion: This preliminary radiogenomics analysis showed associations between MRI features and high-frequency mutations in HBV-related HCCs.

查看原文本刊更多论文

乙型肝炎病毒相关肝细胞癌的初步放射基因组学研究:MRI特征与突变之间的关系

目的:探讨乙型肝炎病毒(HBV)相关肝细胞癌(HCC)的MRI特征与高频突变之间的关系。方法:本研究纳入了58例HCC患者，他们在手术切除前进行了对比增强MRI检查并进行了基因组测序。评估MRI特征和突变信息。结果:HCC中前5位突变基因分别为TP53(53.45%)、TAF1(24.14%)、PDE4DIP(22.41%)、ABCA13(18.97%)和LRP1B(17.24%)。TP53和LRP1B突变分别与肿瘤坏死(p = 0.035)和镶嵌结构(p = 0.015)相关。ABCA13突变与马赛克结构(p = 0.025)和坏死(p = 0.010)相关。结论:这项初步的放射基因组学分析显示，MRI特征与hbv相关hcc的高频突变之间存在关联。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Personalized medicine 医学-药学

CiteScore

3.30

自引率

4.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Personalized Medicine (ISSN 1741-0541) translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape thefuture of medicine by providing a platform for expert commentary and analysis. The journal addresses scientific, commercial and policy issues in the field of precision medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles.